Literature DB >> 27100705

Anandamide and its metabolites: what are their roles in the kidney?

Joseph K Ritter1, Guangbi Li2, Min Xia3, Krishna Boini2.   

Abstract

Anandamide (AEA) is the N-acyl ethanolamide of arachidonic acid, an agonist of cannabinoid and non-cannabinoid receptors in the body. The kidneys are enriched in AEA and in enzymes that metabolize AEA, but the roles of AEA and its metabolites in the kidney remain poorly understood. This system likely is involved in the regulation of renal blood flow and hemodynamics and of tubular sodium and fluid reabsorption. It may act as a neuromodulator of the renal sympathetic nervous system. AEA and its cyclooxygenase-2 metabolites, the prostamides, in the renal medulla may represent a unique antihypertensive system involved in the long-term control of blood pressure. AEA and its metabolites are also implicated as modulators of inflammation and mediators of signaling in inflammation. AEA and its metabolites may be influential in chronic kidney disease states associated with inflammation and cardiovascular diseases associated with hyperhomocysteinemia. The current knowledge of the roles of AEA and its derivatives highlights the need for further research to define and potentially exploit the role of this endocannabinoid system in the kidney.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27100705      PMCID: PMC6267779          DOI: 10.2741/s461

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  73 in total

1.  Uptake blockade of endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition.

Authors:  Daniel T Brozoski; Caron Dean; Francis A Hopp; Jeanne L Seagard
Journal:  Brain Res       Date:  2005-09-09       Impact factor: 3.252

2.  Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP.

Authors:  H Cadas; S Gaillet; M Beltramo; L Venance; D Piomelli
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

Review 3.  Renal medullary blood flow and renal medullary antihypertensive mechanisms.

Authors:  G Bergström; G Göthberg; G Karlström; J Rudenstam
Journal:  Clin Exp Hypertens       Date:  1998-01       Impact factor: 1.749

4.  Production and physiological actions of anandamide in the vasculature of the rat kidney.

Authors:  D G Deutsch; M S Goligorsky; P C Schmid; R J Krebsbach; H H Schmid; S K Das; S K Dey; G Arreaza; C Thorup; G Stefano; L C Moore
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

5.  Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.

Authors:  K D Lake; D R Compton; K Varga; B R Martin; G Kunos
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

6.  Differential mechanisms mediating depressor and diuretic effects of anandamide.

Authors:  Jianping Li; Donna H Wang
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

7.  The endogenous cannabinoid system protects against colonic inflammation.

Authors:  Federico Massa; Giovanni Marsicano; Heike Hermann; Astrid Cannich; Krisztina Monory; Benjamin F Cravatt; Gian-Luca Ferri; Andrei Sibaev; Martin Storr; Beat Lutz
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.

Authors:  Guillermo B Silva; Douglas K Atchison; Luis I Juncos; Néstor H García
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

9.  Functional disassociation of the central and peripheral fatty acid amide signaling systems.

Authors:  Benjamin F Cravatt; Alan Saghatelian; Edward G Hawkins; Angela B Clement; Michael H Bracey; Aron H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

10.  Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.

Authors:  P Janiak; B Poirier; J-P Bidouard; C Cadrouvele; F Pierre; L Gouraud; I Barbosa; J Dedio; J-P Maffrand; G Le Fur; S O'Connor; J-M Herbert
Journal:  Kidney Int       Date:  2007-09-19       Impact factor: 10.612

View more
  11 in total

Review 1.  Endocrine functions of the renal interstitium.

Authors:  Armin Kurtz
Journal:  Pflugers Arch       Date:  2017-06-17       Impact factor: 3.657

Review 2.  Cannabinoids and the kidney: effects in health and disease.

Authors:  Frank Park; Praveen K Potukuchi; Hamid Moradi; Csaba P Kovesdy
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-26

3.  Cannabidiol improves thyroid function via modulating vitamin D3 receptor in vitamin D3 deficiency diet-induced rat model.

Authors:  Mahendra Kumar Trivedi; Sambhu Mondal; Snehasis Jana
Journal:  J Food Sci Technol       Date:  2022-06-23       Impact factor: 3.117

4.  Endocannabinoid System in Polycystic Kidney Disease.

Authors:  Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter
Journal:  Am J Nephrol       Date:  2022-03-09       Impact factor: 4.605

Review 5.  Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease.

Authors:  Virna Margarita Martín Giménez; Sandra Edith Noriega; Diego Enrique Kassuha; Lucía Beatriz Fuentes; Walter Manucha
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-16

Review 6.  A Review of Cannabis in Chronic Kidney Disease Symptom Management.

Authors:  Claudia Ho; Dan Martinusen; Clifford Lo
Journal:  Can J Kidney Health Dis       Date:  2019-02-22

7.  Modulation of Endocannabinoids by Caloric Restriction Is Conserved in Mice but Is Not Required for Protection from Acute Kidney Injury.

Authors:  Karla Johanna Ruth Hoyer-Allo; Martin Richard Späth; Ruth Hanssen; Marc Johnsen; Susanne Brodesser; Kathrin Kaufmann; Katharina Kiefer; Felix Carlo Koehler; Heike Göbel; Torsten Kubacki; Franziska Grundmann; Bernhard Schermer; Jens Brüning; Thomas Benzing; Volker Burst; Roman-Ulrich Müller
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

Review 8.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

Review 9.  The nephrologist's guide to cannabis and cannabinoids.

Authors:  Joshua L Rein
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

10.  The CRISPR-Cas9 crATIC HeLa transcriptome: Characterization of a novel cellular model of ATIC deficiency and ZMP accumulation.

Authors:  Randall C Mazzarino; Veronika Baresova; Marie Zikánová; Nathan Duval; Terry G Wilkinson; David Patterson; Guido N Vacano
Journal:  Mol Genet Metab Rep       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.